Clinical Trial Update: A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer [Phase 2]

View source ↗

Summary

A single-arm, multicenter Phase 2 clinical trial evaluating Becotatug Vedotin plus Zimberelimab for recurrent/metastatic cervical, vulvar, and vaginal cancers; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Becotatug Vedotin
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING